Reviva Pharmaceuticals Holdings, Inc. (RVPH)
NASDAQ: RVPH · Real-Time Price · USD
0.3550
+0.0300 (9.23%)
At close: Jan 13, 2026, 4:00 PM EST
0.3540
-0.0010 (-0.28%)
After-hours: Jan 13, 2026, 7:59 PM EST
RVPH Employees
Reviva Pharmaceuticals Holdings had 14 employees as of December 31, 2024. The number of employees decreased by 1 or -6.67% compared to the previous year.
Employees
14
Change (1Y)
-1
Growth (1Y)
-6.67%
Revenue / Employee
n/a
Profits / Employee
-$1,625,479
Market Cap
41.48M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14 | -1 | -6.67% |
| Dec 31, 2023 | 15 | 5 | 50.00% |
| Dec 31, 2022 | 10 | 5 | 100.00% |
| Dec 31, 2021 | 5 | 0 | - |
| Dec 31, 2020 | 5 | 1 | 25.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RVPH News
- 15 days ago - Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum - GlobeNewsWire
- 21 days ago - FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug - Benzinga
- 21 days ago - Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia - GlobeNewsWire
- 2 months ago - Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025 - GlobeNewsWire
- 3 months ago - Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners - GlobeNewsWire
- 4 months ago - Top 3 Health Care Stocks That May Explode In September - Benzinga
- 4 months ago - Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering - GlobeNewsWire